• Aligning non-lipid delivery strategies with specific modality needs, such as intracellular targeting for gene editing or sustained expression for saRNA
• Evaluating polymers, peptide-based systems, and hybrid carriers for RNA delivery to overcome LNP-specific limitations like reactogenicity
• Benchmarking stability, encapsulation efficiency, and scalability of alternative nanoparticle systems to support early development decisions

NEW COMPANY